Consun Pharmaceutical Group Limited (01681) published its monthly return for the period ended 31 January 2026. The total authorised share capital remained at 5,000,000,000 ordinary shares (HKD 0.1 par value), amounting to HKD 500,000,000. The number of issued shares recorded a net decrease of 6,985,296, bringing the total from 848,493,407 down to 841,508,111.

According to the filing, 1,399,704 new ordinary shares were issued through the exercise of share options under a scheme approved on 2 December 2013, raising HKD 5,650,256.88. Additionally, 8,385,000 shares were redeemed and cancelled, with a further 100,000 shares redeemed but not yet cancelled as of the end of the reporting period. Public float requirements continued to be met at the prescribed 25% threshold.